BillionToOne, Inc.
BLLNInsider Trading
View AllBillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Revenue | $152.58M | $71.73M |
| Cost of Revenue | $71.67M | $54.42M |
| Gross Profit | $80.92M | $17.31M |
| Gross Margin | 53.03% | 24.13% |
| Operating Expenses | $128.06M | $86.80M |
| Operating Income | $-47.15M | $-69.50M |
| Operating Margin | -30.90% | -96.89% |
| Net Income | $-41.57M | $-82.68M |
| Net Margin | -27.24% | -115.27% |
| EPS (Basic) | $-0.93 | $-1.85 |
| EBITDA | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A |
| Price To Sales Ratio | N/A | N/A |
| Shares Outstanding | N/A | N/A |
| Market Capitalization | N/A | N/A |